The companies will develop biomarkers of response to Lantern's lead therapy candidates, including a potential liquid biopsy assay for its NSCLC drug Tavocept.
The Genomics Evidence Neoplasia Information Exchange aims to provide insights through the analysis of data from tens if not hundreds of thousands of patient results.
BMS has provided funding to the diagnostic company to support build-out of its new lab and development of its platform, which they hope can identify new biomarkers for Opdivo.
The company has advanced sequencing-based copy number analyses to assess genomic instablity in CTCs, and used that to develop a method to predict response to PARP inhibitors based on the phenotype, or appearance, of genomically unstable CTCs.
Researchers at the Hartwig Medical Foundation have launched a clinical trial that seeks to match tumor biomarkers with experimental and off-label drugs.
The companies said their partnership will result in a complete solution for biomarker discovery, optimization, and validation on a number of platforms.
The clinical trial is designed to validate that biomarkers, measured in routine urine tests, effectively predict genetic mutations in drug-metabolizing enzymes.
The company has raised venture funding to support commercialization of a variety of blood-based cancer assays in Taiwan, but has yet to publish data validating its approach.
